G51 Stock Overview
An investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Genscript Biotech Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.27 |
| 52 Week High | HK$2.69 |
| 52 Week Low | HK$0.96 |
| Beta | 1.05 |
| 11 Month Change | -9.93% |
| 3 Month Change | -7.30% |
| 1 Year Change | -51.43% |
| 33 Year Change | -68.72% |
| 5 Year Change | -41.74% |
| Change since IPO | 820.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| G51 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -0.8% | -6.9% | -0.2% |
| 1Y | -51.4% | 1.6% | 7.8% |
Return vs Industry: G51 underperformed the German Life Sciences industry which returned 1.3% over the past year.
Return vs Market: G51 underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| G51 volatility | |
|---|---|
| G51 Average Weekly Movement | 9.7% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G51's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: G51's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 7,284 | Weihui Shao | www.genscript.com |
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United States of America, Europe, the People’s Republic of China, Japan, the other Asia Pacific regions, and internationally. The company operates through four segments: Life Science Services and Products; Biologics Development Services; Industrial Synthetic Biology Products; and Cell Therapy. The Life Science Services and Products segment provides products and services in various categories, including DNA synthesis, plasmid DNA preparation, molecular cloning, oligonucleotide synthesis, protein and antibody expression and purification, peptide synthesis, antibody development, IVT RNA production, assay cell line development and vector packing, molecular diagnostics tools, and genome editing tools and reagents, as well as instrument for protein analysis and purification, cell isolation and activation.
Genscript Biotech Corporation Fundamentals Summary
| G51 fundamental statistics | |
|---|---|
| Market cap | €2.75b |
| Earnings (TTM) | -€167.06m |
| Revenue (TTM) | €952.85m |
2.9x
P/S Ratio-16.5x
P/E RatioIs G51 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G51 income statement (TTM) | |
|---|---|
| Revenue | US$1.01b |
| Cost of Revenue | US$468.10m |
| Gross Profit | US$541.49m |
| Other Expenses | US$718.50m |
| Earnings | -US$177.01m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.083 |
| Gross Margin | 53.63% |
| Net Profit Margin | -17.53% |
| Debt/Equity Ratio | 48.1% |
How did G51 perform over the long term?
See historical performance and comparison